PRS Cardiovascular (CV-PRS)

PRS Cardiovascular (CV-PRS)

$1,900.00

A saliva test to assess your genetic risk for 8 common Cardiovascular Conditions, Results in 4–8 weeks. Free Genetic Counseling.
Get a personalized report and a free virtual session to help you understand your risk and take
preventive steps.
* Price includes Comprehensive Genomic Risk Test: report, counseling, and prevention
roadmap.

Code: AGPP-CV-PRS Category:

Polygenic Risk Test – Cardiovascular

Simple DNA Saliva Test To Uncover Your Inherited Risk For 8 Common Cardiovascular Conditions

What Is A Polygenic Score?

  • Everyone has small genetic differences, called variants.
  • These variants can affect the risk of developing certain diseases.
  • A polygenic risk score (PRS) combines the effects of millions of genetic variants to estimate your disease risk.
  • While each variant has a small effect, their combined impact can be significant.
Know More

Who Should Take This Test?

  • This may include people:
  • Seeking personalized strategies for cardiovascular prevention
  • With a family history of cardiovascular conditions
  • With limited or unknown family history
  • Who developed CAD despite lacking traditional risk factors
  • Who have developed a condition without having traditional risk factors.

Why PRS for Cardiovascular /Cardiometabolic Matters

The Polygenic Risk Score (PRS) for cardiovascular conditions is a revolutionary genetic test that helps identify your inherited risk of common cardiovascular conditions.

Single comprehensive test covers 8 cardiometabolic conditions

Enables targeted lifestyle and medical prevention

Access to cutting-edge precision cardiology programs

Identifies genetic risk decades before symptoms. Finds high-risk individuals missed by standard screening

How It Works - Step By Step

The test is powered by the innovative Blended Genome Exome™ technology, developed in collaboration with Broad Clinical Labs at Harvard University and the Massachusetts Institute of Technology.

The technology combines 95.5× whole-exome sequencing (WES) with genome-wide low-coverage whole-genome sequencing (lcWGS) to detect both rare pathogenic variants and polygenic risk with high analytical precision.

Testing is performed through CAP/CLIA accredited laboratories, with advanced analytics support from Allelica and the Laboratory for Molecular Medicine (Mass General Brigham), and regional collaboration with Novo Genomics.

 

Order Now

Equipped with one of the most precise and comprehensive genomic risk assessments available, the test integrates monogenic and polygenic risk into a single, clinically actionable report.

Results are ready in 4 to 8 weeks, enabling you to act early and make informed, proactive health decisions. 

[email protected]